Sherman M R, Tuazon F B, Miller L K
Endocrinology. 1980 Jun;106(6):1715-27. doi: 10.1210/endo-106-6-1715.
Estrogen receptors in cytoplasmic extracts of breast tumors from more than 40 patients were separately analyzed by gel filtration and/or ultracentrifugation under diverse conditions. Resultant patterns are presented for specimens from 11 women with infiltrating duct carcinoma and are representative of results obtained in all samples of sufficient size and receptor content (approximately 40 fmol/mg cytosol protein) for accurate determination of hydrodynamic parameters. Estradiol-binding components of intracellular origin were distinguished from the serum contaminant, sex hormone-binding globulin by their high affinity for diethylstilbestrol and negligible affinity for 5 alpha-dihydrotestosterone. The predominant molecular forms of the receptors, but not the steroid specificity, varied dramatically with experimental factors, including the duration of the fractionation procedure, ionic strength, and the presence of protease inhibitors, particularly the bacterial tripeptides N-acetyl- and N-propionyl-L-leucyl-L-leucyl-DL-arginine aldehydes (leupeptin). At least three discrete forms of the intracellular receptors were detected. The smallest labeled complex, the mero-receptor, with a sedimentation coefficient of about 3S and a Stokes radius of about 24 A, was formed during prolonged analysis of control cytosol in hypotonic or hypertonic buffers. Complexes with an intermediate sedimentation coefficient (approximately 5S) and Stokes radius (approximately 34A) were detected when control cytosol was analyzed rapidly in hypotonic buffer or when cytosol containing 50 nM leupeptin was analyzed in hypertonic buffer. The largest receptor form (10.5S, 71A) was predominant in cytosol prepared with 50 mM leupeptin and analyzed in hypotonic buffer. In this small series of patients, there was no obvious correlation between the molecular form of the receptors and the clinical status or eventual responsiveness to endocrine therapy. Preliminary studies of endogenous proteolytic enzymes in breast tumor cytosol that may be involved in mero-receptor formation included assays of plasminogen activators (EC 3.4.21.-) by fibrinolytic and spectrofluorometric techniques. The detection of high concentrations of plasminogen activators in several tumor cytosols and the inhibition of this activity by leupeptin, which stabilizes the large receptor forms in this and other systems, are consistent with a possible role of these enzymes in receptor cleavage.
对40多名患者乳腺肿瘤细胞质提取物中的雌激素受体,在不同条件下分别通过凝胶过滤和/或超速离心进行分析。给出了11名浸润性导管癌女性患者标本的结果,这些结果代表了所有足够大小和受体含量(约40 fmol/mg胞质溶胶蛋白)的样本所获得的结果,以便准确测定流体动力学参数。通过对己烯雌酚的高亲和力和对5α-二氢睾酮的可忽略不计的亲和力,将细胞内源性雌二醇结合成分与血清污染物性激素结合球蛋白区分开来。受体的主要分子形式,而非类固醇特异性,会随实验因素发生显著变化,这些因素包括分级分离过程的持续时间、离子强度以及蛋白酶抑制剂的存在,特别是细菌三肽N-乙酰基-和N-丙酰基-L-亮氨酰-L-亮氨酰-DL-精氨酸醛(亮抑酶肽)。至少检测到三种不同形式的细胞内受体。最小的标记复合物,即单体受体,沉降系数约为3S,斯托克斯半径约为24 Å,是在低渗或高渗缓冲液中对对照胞质溶胶进行长时间分析时形成的。当在低渗缓冲液中快速分析对照胞质溶胶或在高渗缓冲液中分析含有50 nM亮抑酶肽的胞质溶胶时,检测到沉降系数中等(约5S)和斯托克斯半径(约34 Å)的复合物。最大的受体形式(10.5S,71 Å)在含有50 mM亮抑酶肽制备并在低渗缓冲液中分析时的胞质溶胶中占主导地位。在这一小系列患者中,受体的分子形式与临床状态或最终对内分泌治疗的反应之间没有明显的相关性。对可能参与单体受体形成的乳腺肿瘤胞质溶胶中内源性蛋白水解酶的初步研究,包括通过纤维蛋白溶解和荧光分光光度技术对纤溶酶原激活剂(EC 3.4.21.-)的测定。在几种肿瘤胞质溶胶中检测到高浓度的纤溶酶原激活剂,以及亮抑酶肽对该活性的抑制作用,亮抑酶肽在该系统和其他系统中能稳定大的受体形式,这与这些酶在受体裂解中可能发挥的作用一致。